Efficacy of corticosteroids and external beam radiation in the management of moderate to severe thyroid eye disease

Journal of Neuro-Ophthalmology

Volumn 27, Issue 3, 2007, Pages 205-214

  Zoumalan, Christopher I ^a,g   Cockerham, Kimberly P ^a   Turbin, Roger E ^b   Volpe, Nicholas J ^c   Kazim, Michael ^d   Douglas, Raymond S ^e   Feldon, Steven E ^f  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d New York Presbyterian Hospital   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOGLOBULIN; MEPREDNISONE; PREDNISOLONE; PREDNISONE;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIPOLAR DISORDER; BONE DENSITY; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; ENDOCRINE OPHTHALMOPATHY; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEART PALPITATION; HEMORRHAGIC GASTRITIS; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSOMNIA; INTRAOCULAR HYPERTENSION; MOOD DISORDER; MOON FACE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOLOGY; OSTEOPOROSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; SIDE EFFECT; STOMACH IRRITATION; URINARY TRACT INFECTION; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; EYE; GRAVES OPHTHALMOPATHY; HUMANS; INJECTIONS, INTRAVENOUS; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 34748814944     PISSN: 10708022     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNO.0b013e31814a5ef8     Document Type: Article

References (46)

1. Gorman CA. The measurement of change in Graves' ophthalmopathy. Thyroid 1998;8:539-43.
2. Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf) 2001;55:283-30.
3. Mourits MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 1989;73:639-44.
4. Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy. N Engl J Med 1993;329:1468-75.
5. Jacobson DM. Dysthyroid orbitopathy. Semin Neurol 2000;20:43-54.
6. Kazim M, Goldberg RA, Smith TJ. Insights into the pathogenesis of thyroid-associated orbitopathy: evolving rationale for therapy. Arch Ophthalmol 2002;120:380-6.
7. Werner SC. Classification of the eye changes of Graves' disease. Am J Ophthalmol 1969;68:646-8.
8. Clauser L, Galie M, Sarti E, et al. Rationale of treatment in Graves ophthalmopathy. Plast Reconstr Surg 2001;108:1880-94.
9. Kennerdell JS, Cockerham KP, Maroon JC, et al. Dysthyroid Orbitopathy. In: Kennerdell JS, Cockerham KP, Maroon JC, et al. Practical Diagnosis and Management of Orbital Disease. Boston: Butterworth-Heinemann Press; 2001:53-75.
10. Eckstein A, Quadbeck B, Mueller G, et al. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol 2003;87:773-6.
11. Sergott RC, Glaser JS. Graves' ophthalmopathy. A clinical and immunologic review. Surv Ophthalmol 1981;26:1-21.
12. Prummel MF, Mourits MP, Blank L, et al. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 1993;342:949-54.
13. Weetman AP, Wiersinga WM. Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey. Clin Endocrinol (Oxf) 1998;49:21-8.
14. Marcocci C, Bartalena L, Panicucci M, et al. Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves' ophthalmopathy: a comparative study. Clin Endocrinol (Oxf) 1987;27:33-42.
15. Trobe JD, Glaser JS, Laflamme P. Dysthyroid optic neuropathy. Clinical profile and rationale for management. Arch Ophthalmol 1978;96:1199-209.
16. Ebner R, Devoto MH, Weil D, et al. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol 2004;88:1380-6.
17. Garber MI. Methylprednisolone in the treatment of exophthalmos. Lancet 1966;1:958-60.
18. Hatton MP, Rubin PA. The pathophysiology of thyroid-associated ophthalmopathy. Ophthalmol Clin North Am 2002;15:113-9.
19. Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 2001;108:1523-34.
20. Gorman CA, Garrity JA, Fatourechi V, et al. The aftermath of orbital radiotherapy for graves' ophthalmopathy. Ophthalmology 2002;109:2100-7.
21. Bartalena L, Marcocci C, Chiovato L, et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 1983;56:1139-44.
22. Prummel MF, Bakker A, Wiersinga WM, et al. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience. Eur J Endocrinol 2003;148:491-5.
23. Atabay C, Schrooyen M, Zhang ZG, et al. Use of eye muscle antibody measurements to monitor response to plasmapheresis in patients with thyroid-associated ophthalmopathy. J Endocrinol Invest 1993;16:669-74.
24. Burrow GN, Mitchell MS, Howard RO, et al. Immunosuppressive therapy for the eye changes of Graves' disease. J Clin Endocrinol Metab 1970;31:307-11.
25. Claridge KG, Ghabrial R, Davis G, et al. Combined radiotherapy and medical immunosuppression in the management of thyroid eye disease. Eye 1997;11:717-22.
26. Yamamoto K, Saito K, Takai T, et al. Treatment of Graves' ophthalmopathy by steroid therapy, orbital radiation therapy, plasmapheresis and thyroxine replacement. Endocrinol Jpn 1982;29:495-501.
27. Antonelli A, Saracino A, Alberti B, et al. High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy. Acta Endocrinol (Copenh) 1992;126:13-2.
28. Prummel MF, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 1989;321:1353-9.
29. Bartalena L, Marocci C, Bogazzi F, et al. Glucocorticoid therapy of Graves' ophthalmopathy. Exp Clin Endocrinol 1991;97:320-7.
30. Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001;86:3562-7.
31. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338:73-8.
32. Macchia PE, Bagattini M, Lupoli G, et al. High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy. J Endocrinol Invest 2001;24:152-8.
33. Kahaly GJ, Pitz S, Hommel G, et al. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 2005;90:5234-40.
34. Baschieri L, Antonelli A, Nardi S, et al. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy. Thyroid 1997;7:579-85.
35. Noth D, Gebauer M, Muller B, et al. Graves' ophthalmopathy: natural history and treatment outcomes. Swiss Med Wkly 2001;131:603-9.
36. Koshiyama H, Koh T, Fujiwara K, et al. Therapy of Graves' ophthalmopathy with intravenous high-dose steroid followed by orbital irradiation. Thyroid 1994;4:409-13.
37. Matejka G, Verges B, Vaillant G, et al. Intravenous methylprednisolone pulse therapy in the treatment of Graves' ophthalmopathy. Horm Metab Res 1998;30:93-8.
38. Kendall-Taylor P, Crombie AL, Stephenson AM, et al. Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy. Bmj 1988;297:1574-8.
39. Staar S, Muller RP, Hammer M, et al. Results and prognostic factors in retrobulbar radiotherapy combined with systemic corticosteroids for endocrine orbitopathy (Graves' disease). Front Radiat Ther Oncol 1997;30:206-17.
40. Tagami T, Tanaka K, Sugawa H, et al. High-dose intravenous steroid pulse therapy in thyroid-associated ophthalmopathy. Endocr J 1996;43:689-99.
41. Dandona P, Havard CW, Mier A. Methylprednisolone and Graves' ophthalmopathy. Bmj 1989;298:830.
42. Chang TC, Huang KM, Hsiao YL, et al. Relationships of orbital computed tomographic findings and activity scores to the prognosis of corticosteroid therapy in patients with Graves' ophthalmopathy. Acta Ophthalmol Scand 1997;75:301-4.
43. Kazim M, Trokel S, Moore S. Treatment of acute Graves orbitopathy. Ophthalmology 1991;98:1443-8.
44. Hiromatsu Y, Kojima K, Ishisaka N, et al. Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy. Thyroid 1992;2:299-305.
45. Gursoy A, Cesur M, Erdogan MF, et al. New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a patient with Graves' ophthalmopathy. Endocrine 2006;29:513-6.
46. Weissel M, Hauff W. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid 2000;10:521.